FDA tightens reins on doctors praising unapproved drugs

02/1/2010 | NYTimes.com

The FDA is closely monitoring drug companies' marketing activities and may also be clamping down on doctors who tout medicines that haven't yet received agency approval, as evidenced by a warning letter sent to a prominent Miami dermatologist who publicly praised an unapproved injectable antiwrinkle drug. "We have been talking about new products in the pipeline for years, and I think there is nothing wrong with that. But we are going to have to keep our opinions to ourselves," said another dermatologist, who suggests doctors may be unclear as to what they are permitted to say.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations